Fludarabine phosphate in lymphoma: an important new therapeutic agent.
McLaughlin
P
P
Department of Hematology, U.T.M.D. Anderson Cancer Center, Houston 77030, USA.
Robertson
L E
LE
Keating
M J
MJ
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D009101:Multiple Myeloma / Q000188:drug therapy; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate